{"entity":{"id":"nct05415072","kind":"trial","name":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas","aka":[],"tldr":"A phase 1/2 trial of DYP688 in uveal melanoma, run by Novartis Pharmaceuticals, active and no longer recruiting.","summary":"A Phase I/II Study of DYP688 in Patients With Metastatic Uveal Melanoma and Other GNAQ/11 Mutant Melanomas is a phase 1/2 interventional study registered as NCT05415072 by Novartis Pharmaceuticals, with 66 participants enrolled, started 2022-07-04 and due to reach its primary completion in 2027-10-01. Interventions recorded: DYP688.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT05415072","url":"https://clinicaltrials.gov/study/NCT05415072"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["uveal-melanoma"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["advanced-accelerator-applications"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT05415072","phase":"1/2","setting":"A Phase I/II, Multi-center, Open Label Study of DYP688 in Patients With Metastatic Uveal Melanoma (MUM) and Other GNAQ/11 Mutant Melanomas","sponsor":"Novartis Pharmaceuticals","enrolled":66,"outcomes":[]},"route":"/trials/nct05415072/","neighbours":{"cancer":[{"id":"uveal-melanoma","kind":"cancer","name":"Uveal melanoma","route":"/cancers/uveal-melanoma/"}],"company":[{"id":"advanced-accelerator-applications","kind":"company","name":"Advanced Accelerator Applications (Novartis)","route":"/companies/advanced-accelerator-applications/"}]}}